Will FDA Approve ‘Female Viagra’?

The drug flibanserin, designed to treat hypoactive sexual desire disorder (HSDD), also known as chronic low libido, is on its way to be evaluated by the Food and Drug Administration. If it does get FDA approval, it would be the first medication officially sanctioned by regulators.

Until, that is, you factor in a vocal pro-licensing lobby, comprising a coalition of women’s groups backed by the drug’s current manufacturer, Sprout, campaigning under the banner “Even the Score.” They say “institutionalised sexism” has stopped sexual dysfunction in women getting the same medical attention as that in men. Female low libido is a common problem among today’s women, who are often attempting to meet the demands of work, family life and battle issues within a relationship.

But the positive results of trials has been set off its pedestal by safety fears. The medicine flibanserin, made by Sprout Pharmaceuticals, small drugmaker from North Carolina, is made to increase the desire in human being’s better looking gender.

The FDA has rejected the drug in the past, raising concerns over side effects that include low blood pressure and drowsiness. The drug will be the first of its kind that is approved by an official agency should it pass trials, Daily Mail reported.

Many industry experts are anxious going by Sprout’s previous record who see a troubling pattern in the aggressive tactics it has used to urge the FDA to approve the women’s desire drug because of lacklustre effectiveness and side effects such as nausea, dizziness and fainting. Companies Pfizer, Bayer and Procter & Gamble who all studied, but then abandoned the prospective treatments for decrease in woman’s sexual desire.